A Multi-Center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib.

Trial Profile

A Multi-Center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Mar 2014 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
    • 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register DRKS00003938).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top